Printer Friendly

New resources focus on continuing Cox-2 dangers.

On the heels of Vioxx's withdrawal from the world market last fall, the FDA asked Pfizer in April to voluntarily withdraw its arthritis and acute-pain medication, Bextra, from the U.S. market. At the same time, the FDA recommended a "black box" warning for Pfizer's painkiller Celebrex.

In response to plaintiff members' need for timely information, the ATLA Exchange and ATLA Education have created new resources for cases in which clients have suffered adverse effects from these drugs.

Bextra is a Cox-2 nonsteroidal anti-inflammatory drug (NSAID) like Vioxx and Celebrex. The FDA found Bextra to be associated with potential increased risk for serious cardiovascular side effects and an increased risk of serious skin reactions. Pfizer agreed to withdraw Bextra from the market pending further discussion with the FDA, as it did when European regulators made a similar request. The company says it will take similar appropriate measures based on discussions with other regulatory agencies around the world.

The Exchange's new Bextra Litigation Packet contains sample complaints and a client intake form; a time line of significant regulatory events; ATLA Education materials; FDA resources; similar matters from the Exchange database; abstracts of medical and scientific journal articles; references to selected newspaper headlines; and information on other ATLA resources on the topic, including the Vioxx Litigation Group (which addresses all Cox-2 NSMDs), the Products Liability Section, and the Section on Toxic, Environmental, and Pharmaceutical Torts. This packet follows the Vioxx Litigation Packet and Vioxx Update Packet.

For more information, go to www.exchange.aria.org and click on "Litigation Packets," or call the Exchange at (800) 344-3023.

ATLA Education has sponsored several programs on Cox-2 developments. For example, in May it held a Vioxx mock trial, cosponsored by the Vioxx Litigation Group, in New Orleans. The two-day seminar, for litigation group members only, allowed participants to test potential liability theories and defenses in front of a live focus group. A recent teleseminar, open to ATLA plaintiff members only, covered the FDA's recall of Bextra and the "black box" warnings required for Celebrex.

Purchase audio recordings of this and other ATLA Education programs by visiting www.playbacknow.com/atla or calling (800) 241-7785. Audio and video recordings of the Vioxx program are available to litigation group members only.
COPYRIGHT 2005 American Association for Justice
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:The Exchange
Publication:Trial
Date:Jun 1, 2005
Words:375
Previous Article:Two states limit tort victims' rights.
Next Article:Section members get free research material.


Related Articles
BEST DATA TO PROVIDE COX CABLE MODEMS.
DRINK CONTEST OFFERS TIPS TO RING IN SOBER SEASON.
SARS measure halts adoptions from China.
LANCASTER MAN TO BE TRIED IN FATAL CRASH.
SMU's Cox School of Business looks to the future with extreme networks.
BLM seeks increase in herbicide use.
The Cox revolution: how the former U.S. lawmaker is changing the SEC.
Regulatory agencies' revolving door drives imminent change.
Chair's corner.
Judge weighs penalty for activist.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters